2 active not recruiting, 1 completed. 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow AIQ Solutions: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comprehensive Assessment of Cancer Theranostic Response TRAQinform Theranostics - Prostate Cancer | Not applicable | Active not recruiting | AIQ Solutions | 25 | 2024-12-02 | 2026-10-06 |
| TRAQinform Assessment of Immunotherapy Response Non-Interventional - Melanoma | Completed | AIQ Solutions | 26 | 2023-06-23 | 2025-08-28 | |
| pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer pTVG-HP, Nivolumab, GM-CSF - Prostate Cancer | Phase 2 | Active not recruiting | University of Wisconsin, Madison | 19 | 2018-09-10 | 2026-06-01 |
Prostatic Neoplasms (2) · Melanoma (1)
Granulocyte-Macrophage Colony-Stimulating Factor (1) · Nivolumab (1) · sargramostim (1)
United States (3)
Hamid Emamekhoo (1)
R44CA257253 (1), R44CA285006 (1)